



ASX ANNOUNCEMENT

13 May 2014

Cynata to Participate in Major International Stem Cell Conference

Cynata Therapeutics Ltd (ASX:CYP), announced today that it has been invited to participate in the World Stem Cell and Regenerative Congress in London being held on May 20-22. The Company further announces that an application to the Victoria State Government for funding under the Technology Trade and International Partnering (TRIP) Program – Biotechnology and Small Technology has been successful. Financial assistance provided under this program will assist Cynata in attending this Congress, with payment of the grant being contingent upon satisfactory completion of certain post-event paperwork.

“The World Congress is probably the most important annual forum for business interaction in the stem cell and regenerative medicine field,” said Dr Ross Macdonald, Chief Executive Officer of Cynata Therapeutics. “Besides attending the Congress we will also use this opportunity to meet with regulatory agencies as part of our plan to bring the Cymerus™ technology into the clinic and eventually to the market and we have scheduled meetings with potential partners, consistent with our strategy of engagement. We are delighted to have been selected for the TRIP grant, for which we thank the Victoria State Government.”

Media contacts: Dr Ross Macdonald, CEO: Tel: 0412 119343; email ross.macdonald@cynata.com
Dr Stewart Washer, Executive Chairman: Tel: 0418 288212; email stewart.washer@cynata.com

About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Ltd (ASX: CYP) is an Australian stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™, originating from the University of Wisconsin-Madison, a world leader in stem cell research. The proprietary Cymerus™ technology seeks to address a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. Cymerus™ does so through the production of a particular type of MSC precursor, called a mesenchymoangioblast (MCA). The Cymerus™ MCA platform provides a source of MSCs that is independent of donor limitations and provides a potential “off-the-shelf” stem cell platform for therapeutic product use, with a pharmaceutical business model and economies of scale. This has the potential to create a new standard in the emergent arena of stem cell therapeutics and provides both a unique differentiator and an important competitive position.